Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-006848
Filing Date
2025-05-08
Accepted
2025-05-08 07:00:23
Documents
83
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lqda-20250331x10q.htm   iXBRL 10-Q 1751659
2 EX-31.1 lqda-20250331xex31d1.htm EX-31.1 15195
3 EX-31.2 lqda-20250331xex31d2.htm EX-31.2 15224
4 EX-32.1 lqda-20250331xex32d1.htm EX-32.1 7457
5 EX-32.2 lqda-20250331xex32d2.htm EX-32.2 7464
6 GRAPHIC lqda-20250331x10q002.jpg GRAPHIC 631
  Complete submission text file 0001558370-25-006848.txt   8260644

Data Files

Seq Description Document Type Size
7 EX-101.SCH lqda-20250331.xsd EX-101.SCH 70449
8 EX-101.CAL lqda-20250331_cal.xml EX-101.CAL 53085
9 EX-101.DEF lqda-20250331_def.xml EX-101.DEF 226556
10 EX-101.LAB lqda-20250331_lab.xml EX-101.LAB 539412
11 EX-101.PRE lqda-20250331_pre.xml EX-101.PRE 372584
86 EXTRACTED XBRL INSTANCE DOCUMENT lqda-20250331x10q_htm.xml XML 1409773
Mailing Address 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560
Business Address 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560 919.328.4400
Liquidia Corp (Filer) CIK: 0001819576 (see all company filings)

EIN.: 851710962 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39724 | Film No.: 25923767
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)